Xponance’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $8.16M | Buy |
25,017
+1,860
| +8% | +$607K | 0.07% | 232 |
|
|
2025
Q1 | $6.25M | Buy |
23,157
+701
| +3% | +$189K | 0.06% | 251 |
|
|
2024
Q4 | $5.28M | Buy |
22,456
+1,806
| +9% | +$425K | 0.05% | 296 |
|
|
2024
Q3 | $5.68M | Sell |
20,650
-426
| -2% | -$117K | 0.05% | 274 |
|
|
2024
Q2 | $5.12M | Buy |
21,076
+1,378
| +7% | +$335K | 0.05% | 279 |
|
|
2024
Q1 | $2.94M | Buy |
19,698
+5,609
| +40% | +$838K | 0.03% | 420 |
|
|
2023
Q4 | $2.7M | Sell |
14,089
-895
| -6% | -$171K | 0.03% | 399 |
|
|
2023
Q3 | $2.65M | Buy |
14,984
+109
| +0.7% | +$19.3K | 0.04% | 382 |
|
|
2023
Q2 | $2.83M | Sell |
14,875
-1,963
| -12% | -$373K | 0.04% | 374 |
|
|
2023
Q1 | $3.37M | Buy |
16,838
+161
| +1% | +$32.3K | 0.05% | 331 |
|
|
2022
Q4 | $3.96M | Buy |
16,677
+2,352
| +16% | +$559K | 0.06% | 279 |
|
|
2022
Q3 | $2.87M | Buy |
14,325
+22
| +0.2% | +$4.4K | 0.06% | 308 |
|
|
2022
Q2 | $2.09M | Buy |
14,303
+520
| +4% | +$75.8K | 0.04% | 364 |
|
|
2022
Q1 | $2.25M | Buy |
13,783
+387
| +3% | +$63.2K | 0.04% | 348 |
|
|
2021
Q4 | $2.27M | Buy |
13,396
+9
| +0.1% | +$1.53K | 0.04% | 348 |
|
|
2021
Q3 | $2.53M | Sell |
13,387
-326
| -2% | -$61.6K | 0.05% | 304 |
|
|
2021
Q2 | $2.33M | Buy |
13,713
+1,658
| +14% | +$281K | 0.04% | 331 |
|
|
2021
Q1 | $1.7M | Sell |
12,055
-24
| -0.2% | -$3.39K | 0.04% | 352 |
|
|
2020
Q4 | $1.57M | Buy |
12,079
+114
| +1% | +$14.8K | 0.03% | 356 |
|
|
2020
Q3 | $1.74M | Buy |
11,965
+137
| +1% | +$19.9K | 0.04% | 310 |
|
|
2020
Q2 | $1.75M | Buy |
+11,828
| New | +$1.75M | 0.05% | 285 |
|